Cerebrolysin and cognitive measures in childhood autism and Asperger syndrome
M. G. Krasnoperova, V. M. Bashina, I. A. Skvortsov, N. V. Simashkova · 2003 · Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(6):15–18. PMID 12872620.
Reported findings and study design
Uncontrolled inpatient treatment series. The authors combined clinical observation with instrument-assisted testing of cognition and communication.
Dose, route and schedule
The indexed abstract describes 0.1 mL per microinjection by intramuscular and perineural routes over five days. The same-year companion article specifies ten microinjections per day for five sessions. This describes a historical research procedure.
Protocol source ↗ · Original indexed abstract and same-year companion article
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Positive effects | 89% in childhood autism and 8/8 in the Asperger subgroup | The abstract reports greater cognitive change in the Asperger subgroup (p < 0.005). |
| Domains with reported changes | Expressive and receptive language, fine motor performance, and play | |
| Moderate or marked global improvement | The likely overlapping companion report gives 10% and 63%, respectively, using its stricter Clinical Global Impression threshold. | |
| Safety | The indexed abstract reports no negative effects. The small series does not establish safety. |
The 89% and 100% figures describe positive effects as summarized in the indexed abstract. The companion article applied a different threshold for global improvement. Neither analysis included an untreated comparator.
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- All children received treatment. Differences between diagnostic subgroups cannot estimate benefit versus placebo.
- The companion article describes concurrent rehabilitation and a stricter global-improvement endpoint. Full text for the indexed paper was not located.
Related publications may cover the same research program or participants.
Source access
Original indexed abstract and a same-year article by the same research team. The companion article matches the group sizes and procedure and is treated as likely overlapping.
Source reviewed 2026-11-10.
Source type: Original clinical journal article
Citation and original source
Original source: M. G. Krasnoperova, V. M. Bashina, I. A. Skvortsov, N. V. Simashkova. Cerebrolysin and cognitive measures in childhood autism and Asperger syndrome Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(6):15–18. PMID 12872620. 2003.
Molekul research summary: https://molekul.io/research/cerebrolysin-krasnoperova-autism-2003. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry